ALS/FTD Program

About Selonterra

Selonterra is a private, pre-revenue biotech startup pioneering a novel approach to neurodegenerative diseases. The company's platform integrates human genetics with gene expression network analysis to identify unexploited, druggable targets, with initial programs targeting Alzheimer's (APOE4) and Parkinson's disease (SNCA, LRRK2). Led by a team of experienced industry veterans, the company is advancing its lead small molecule compounds through lead optimization towards IND-enabling studies. Selonterra aims to develop accessible, convenient oral therapies that address the root causes of these devastating conditions.

Therapeutic Areas